Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-17 20:04 | 2026-03-16 | ORKA | Oruka Therapeutics, Inc. | Quinlan Paul T | Officer | SELL | $41.30 | 733 | $30,273 | 31,767 |
| 2026-03-17 21:03 | 2026-03-16 | UPB | Upstream Bio, Inc. | GRAY MICHAEL | Officer | SELL | $9.29 | 852 | $7,915 | 29,648 |
| 2026-03-18 00:34 | 2026-03-17 | IRWD | IRONWOOD PHARMACEUTICALS INC | DENNER ALEXANDER J | Director | SELL | $3.05 | 6,730,800 | $20,530,286 | 9,188,635 |
| 2026-03-18 00:00 | 2026-03-16 | CYRX | Cryoport, Inc. | Sawicki Mark W | Officer | SELL | $8.00 | 3,235 | $25,880 | 103,697 |
| 2026-03-18 00:00 | 2026-03-16 | CYRX | Cryoport, Inc. | SHELTON JERRELL | Director, Officer | SELL | $8.00 | 7,918 | $63,344 | 1,054,501 |
| 2026-03-18 00:01 | 2026-03-16 | CYRX | Cryoport, Inc. | ZECCHINI EDWARD J | Officer | SELL | $8.00 | 2,014 | $16,112 | 109,719 |
| 2026-03-17 23:30 | 2026-03-16 | MIRM | Mirum Pharmaceuticals, Inc. | Peetz Christopher | Director, Officer | OPT+S | $91.98 | 40,985 | $3,769,714 | 194,309 |
| 2026-03-17 23:30 | 2026-03-16 | MIRM | Mirum Pharmaceuticals, Inc. | Howe Jolanda | Officer | OPT+S | $91.98 | 4,732 | $435,239 | 8,429 |
| 2026-03-17 23:30 | 2026-03-16 | MIRM | Mirum Pharmaceuticals, Inc. | Radovich Peter | Officer | OPT+S | $91.98 | 16,515 | $1,519,015 | 40,272 |
| 2026-03-17 23:30 | 2026-03-16 | MIRM | Mirum Pharmaceuticals, Inc. | Ramasastry Saira | Director | OPT+S | $90.76 | 2,000 | $181,520 | 0 |
| 2026-03-17 23:30 | 2026-03-16 | MIRM | Mirum Pharmaceuticals, Inc. | Quan Joanne | Officer | OPT+S | $91.98 | 7,287 | $670,243 | 18,864 |
| 2026-03-17 23:30 | 2026-03-16 | MIRM | Mirum Pharmaceuticals, Inc. | BJERKHOLT ERIC | Officer | OPT+S | $91.98 | 7,287 | $670,243 | 49,788 |
| 2026-03-17 22:01 | 2026-03-13 | NGNE | Neurogene Inc. | Cvijic Christine Mikail | Officer | SELL | $20.81 | 4,045 | $84,176 | 105,798 |
| 2026-03-17 22:01 | 2026-03-13 | NGNE | Neurogene Inc. | Cobb Stuart | Officer | SELL | $20.81 | 6,797 | $141,446 | 30,497 |
| 2026-03-17 22:10 | 2026-03-16 | TERN | Terns Pharmaceuticals, Inc. | Burroughs Amy L. | Director, Officer | OPT+S | $46.71 | 14,583 | $681,108 | 288,976 |
| 2026-03-17 21:36 | 2026-03-16 | BCAX | Bicara Therapeutics Inc. | Cohlhepp Ryan | Director, Officer | OPT+S | $19.66 | 12,500 | $245,714 | 200,641 |
| 2026-03-17 21:23 | 2026-03-13 | STOK | Stoke Therapeutics, Inc. | LEVIN ARTHUR A | Director | SELL | $36.80 | 605 | $22,264 | 4,237 |
| 2026-03-17 21:10 | 2026-03-13 | NATR | NATURES SUNSHINE PRODUCTS INC | Norman Daniel C | Officer | SELL | $24.52 | 15,383 | $377,191 | 55,693 |
| 2026-03-17 21:11 | 2026-03-16 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $533.90 | 9,500 | $5,072,019 | 40,513 |
| 2026-03-17 20:51 | 2026-03-17 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Officer | OPT+S | $25.65 | 417 | $10,696 | 76,140 |
| 2026-03-17 20:56 | 2026-03-17 | UTHR | UNITED THERAPEUTICS Corp | MALCOLM JAN | Director | SELL | $533.51 | 45 | $24,008 | 125 |
| 2026-03-17 20:08 | 2026-03-16 | ORKA | Oruka Therapeutics, Inc. | Sandler Laura Lee | Officer | SELL | $41.30 | 600 | $24,780 | 236,984 |
| 2026-03-17 20:09 | 2026-03-16 | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | Officer | SELL | $41.30 | 395 | $16,314 | 18,863 |
| 2026-03-17 20:10 | 2026-03-16 | ORKA | Oruka Therapeutics, Inc. | Klein Lawrence Otto | Director, Officer | SELL | $41.30 | 1,729 | $71,408 | 927,309 |
| 2026-03-16 17:09 | 2026-03-13 | NATR | NATURES SUNSHINE PRODUCTS INC | Lanoy Jonathan David | Officer | SELL | $24.70 | 4,000 | $98,800 | 46,405 |
| 2026-03-16 20:31 | 2026-03-12 | NUVL | Nuvalent, Inc. | Pelish Henry E. | Officer | OPT+S | $98.08 | 35,104 | $3,442,856 | 65,604 |
| 2026-03-16 22:53 | 2026-03-13 | EQ | Equillium, Inc. | Zedelmayer Christine | Officer | OPT+S | $2.50 | 120,312 | $300,816 | 62,586 |
| 2026-03-16 22:05 | 2026-03-12 | BBIO | BridgeBio Pharma, Inc. | Kumar Neil | Director, Officer | SELL | $68.76 | 80,000 | $5,501,072 | 4,438,447 |
| 2026-03-16 20:29 | 2026-03-16 | ABEO | ABEONA THERAPEUTICS INC. | Vazzano Joseph Walter | Officer | SELL | $4.76 | 785 | $3,737 | 567,775 |
| 2026-03-16 20:09 | 2026-03-13 | ZLAB | Zai Lab Ltd | Smiley Joshua L | Officer | OPT+S | $18.63 | 1,966 | $36,623 | 91,026 |
| 2026-03-16 20:08 | 2026-03-13 | ZLAB | Zai Lab Ltd | Edmondson Frazor Titus III | Officer | OPT+S | $18.63 | 1,281 | $23,862 | 6,494 |
| 2026-03-16 20:08 | 2026-03-13 | ZLAB | Zai Lab Ltd | Chen Yajing | Officer | OPT+S | $18.63 | 1,703 | $31,723 | 19,999 |
| 2026-03-16 12:02 | 2026-03-13 | MBX | MBX Biosciences, Inc. | Hawryluk P. Kent | Director, Officer | BUY | $28.41 | 18,500 | $525,663 | 486,777 |
| 2026-03-16 21:20 | 2026-03-12 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Officer | OPT+S | $26.61 | 20,406 | $542,973 | 76,140 |
| 2026-03-16 20:07 | 2026-03-13 | ZLAB | Zai Lab Ltd | Amado Rafael | Officer | OPT+S | $18.63 | 2,957 | $55,083 | 44,757 |
| 2026-03-16 20:08 | 2026-03-13 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Khattar Jack A. | Director, Officer | SELL | $50.38 | 35,000 | $1,763,125 | 958,100 |
| 2026-03-16 20:07 | 2026-03-12 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Hudson Frederick M. | Director | SELL | $50.61 | 5,369 | $271,725 | 60,413 |
| 2026-03-17 01:35 | 2026-03-12 | CYRX | Cryoport, Inc. | STEFANOVICH ROBERT | Officer | OPT+S | $7.78 | 41,443 | $322,331 | 280,371 |
| 2026-03-16 20:31 | 2026-03-16 | UTHR | UNITED THERAPEUTICS Corp | Olian Judy D. | Director | SELL | $535.44 | 200 | $107,088 | 4,445 |
| 2026-03-16 20:30 | 2026-03-13 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $538.00 | 9,500 | $5,110,967 | 130 |
| 2026-03-16 12:30 | 2026-03-12 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $537.81 | 9,500 | $5,109,148 | 130 |
| 2026-03-16 20:15 | 2026-03-13 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $48.91 | 5,280 | $258,245 | 96,200 |
| 2026-03-16 21:14 | 2026-03-16 | CYTK | CYTOKINETICS INC | Callos Andrew | Officer | SELL | $61.03 | 1,709 | $104,300 | 46,149 |
| 2026-03-13 20:11 | 2026-03-11 | VRTX | VERTEX PHARMACEUTICALS INC / MA | McKechnie Duncan | Officer | SELL | $498.42 | 2,633 | $1,312,340 | 12,489 |
| 2026-03-13 20:35 | 2026-03-11 | DYN | Dyne Therapeutics, Inc. | Kersten Dirk | Director | SELL | $19.52 | 129,672 | $2,530,562 | 4,644,386 |
| 2026-03-14 00:30 | 2026-03-12 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Randhawa Simrat | Officer | OPT+S | $81.48 | 33,830 | $2,756,468 | 0 |
| 2026-03-14 00:30 | 2026-03-12 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Garcia Marino | Director, Officer | OPT+S | $81.49 | 122,918 | $10,016,379 | 0 |
| 2026-03-14 00:30 | 2026-03-12 | DNTH | Dianthus Therapeutics, Inc. /DE/ | CARR EDWARD | Officer | OPT+S | $81.49 | 43,682 | $3,559,493 | 0 |
| 2026-03-14 00:16 | 2026-03-13 | XENE | Xenon Pharmaceuticals Inc. | MORTIMER IAN | Director, Officer | OPT+S | $55.23 | 7,308 | $403,584 | 19,923 |
| 2026-03-14 00:16 | 2026-03-13 | XENE | Xenon Pharmaceuticals Inc. | DiFabio Andrea | Officer | OPT+S | $55.23 | 1,342 | $74,112 | 7,301 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.